Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;57(5):511-3.

Clinical presentation and management of suspected ribavirin toxicosis in a dog

Kimberly Bridges  1 , Nicole Beckel  1 , Claire Sharp  1 , Laura Stern  1
Affiliations

Clinical presentation and management of suspected ribavirin toxicosis in a dog

Kimberly Bridges et al. Can Vet J. 2016 May.

Abstract
in English, French

A 5-month-old pit bull terrier was presented for evaluation of progressive lethargy, vomiting, diarrhea, and anorexia 45 hours after ingestion of 625 mg/kg body weight (BW) (9000 mg) of the antiviral medication, ribavirin. Abnormalities that were detected included dehydration, tachycardia, elevated liver enzymes, and prolonged prothrombin time. The dog was discharged after 5 days of aggressive supportive care consisting of intravenous fluids, antiemetics, gastroprotectants, hepatoprotectants, dextrose supplementation, and vitamin B/K1 supplementation.

Présentation clinique et gestion d’une toxicose à la ribavirine suspectée chez un chien. Un chien Pit bull Terrier âgé de 5 mois a été présenté pour l’évaluation d’un abattement progressif, de vomissements, de diarrhée et d’une anorexie 45 heures après l’ingestion de 625 mg/kg poids corporel (PC) du médicament antiviral ribavirine. Les anomalies détectées incluaient la déshydratation, la tachycardie, des enzymes hépatiques élevés et un temps de prothrombine prolongé. Le chien a reçu son congé après 5 jours de soins de soutien agressifs composés de liquides intraveineux, d’antiémétiques, de gastroprotectants, d’hépatoprotectants, de supplémentation en dextrose et de supplémentation en vitamine B/K1.(Traduit par Isabelle Vallières).

PubMed Disclaimer

References

    1. Sidwell RW, Robins RK, Hillyard IW. Ribavirin: An antiviral agent. Pharmacol Ther. 1979;6:123–146. - PubMed
    1. McCormick JB, Mitchell SW, Getchell JP, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet. 1984;15:1367–1369. - PubMed
    1. Bodsworth N, Cooper DA. Ribavirin: A Role in HIV Infection? J Acquir Immune Defic Syndr. 1990;3:893–895. - PubMed
    1. Chan AHW, Partovi N, Ensom MHH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C — A critical review. Ann Pharmacother. 2009;43:2044–2063. - PubMed
    1. Koh C, Liang TJ. What is the future of ribavirin therapy for hepatitis C? Antiviral Res. 2014;104:34–39. - PMC - PubMed

MeSH terms

LinkOut - more resources